Author: Antonin Blandin
Nov2024
Ariana reaffirms its position on drug development and publishes its new manifesto.
We all share the same challenge: finding the right therapy for the right patient. Yet, failures remain frequent, costs continue to soar and over 12,000 diseases still have no treatment. What if you reimagine your drug development process with explainable AI? A methodology where the amount of available data doesn’t matter because we go beyond […]
Nov2024
Ariana Pharma enters a new era with Dr. Pascale Bouillé taking the helm of the company.
Pascale Bouillé is the CEO of Ariana Pharma, where she leverages her extensive expertise in biotechnology to drive innovation and deliver impactful solutions in data-driven drug development. Her career spans significant achievements in both academia and entrepreneurship, reflecting a unique ability to transform cutting-edge scientific discoveries into successful commercial ventures. Before joining Ariana Pharma, Pascale […]
Oct2024
CorpusAnalytiX and Ariana Pharma Announce Collaborative Alliance to Accelerate AI-Driven Drug Development
Collaboration connects CorpusAnalytiX’s diverse healthcare data marketplace with Ariana Pharma’s Knowledge Extraction and Management eXplainable AI platform to fuel advanced pharmaceutical research. October 15, 2024 – LONDON and PARIS: CorpusAnalytiX, a transformative healthcare data brokerage platform, and Ariana Pharma, a leading AI drug development company, today announced a strategic partnership to accelerate drug development and […]